SOURCE: AtheroGenics, Inc.

January 03, 2008 09:29 ET

AtheroGenics to Present at JPMorgan Healthcare Conference on January 10, 2008

ATLANTA, GA--(Marketwire - January 3, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, will be presenting a company overview and update at the upcoming 26th Annual JPMorgan Healthcare Conference on Thursday, January 10, 2008, at 10:00 a.m. PT at the Westin St. Francis in San Francisco, CA.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). AtheroGenics has completed patient enrollment in ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), a Phase III clinical trial evaluating its oral anti-inflammatory and antioxidant lead candidate, AGI-1067, in patients with diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit

Contact Information


    AtheroGenics, Inc.
    Donna L. Glasky
    Corporate Communications
    Email Contact

    Media Inquiries
    Jayme Maniatis / Dana Conti
    Schwartz Communications, Inc.
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    Email Contact